Market Research Logo

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Revie

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene’s lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. The company develops its vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes that recognized by an antibody with antitumor activity. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd Key Recent Developments

Oct 01,2018: Imugene names Professor Pravin Kaumaya to Scientific Advisory Board
Sep 23,2018: Imugene appoints gastrointestinal cancer expert to Scientific
Sep 23,2018: Imugene appoints gastrointestinal cancer expert to Scientific
Sep 23,2018: Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
Sep 23,2018: Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Imugene Ltd - Key Facts
Imugene Ltd - Key Employees
Imugene Ltd - Key Employee Biographies
Imugene Ltd - Major Products and Services
Imugene Ltd - History
Imugene Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Imugene Ltd - Business Description
Imugene Ltd - Corporate Strategy
Imugene Ltd - SWOT Analysis
SWOT Analysis - Overview
Imugene Ltd - Strengths
Imugene Ltd - Weaknesses
Imugene Ltd - Opportunities
Imugene Ltd - Threats
Imugene Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Imugene Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 31, 2018: Imugene: Business Update - Appendix 4C for the quarter ended 30 June 2018
Jul 31, 2018: Imugene: Business Update - Appendix 4C for the quarter ended 30 June 2018
Jul 23, 2018: Imugene: PD-1 cancer vaccine development update
Mar 28, 2018: Leslie Chong Appointed as Managing Director
Oct 10, 2017: Imugene Receives $1.1 million in Research and Development Tax Refund
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Imugene Ltd, Key Facts
Imugene Ltd, Key Employees
Imugene Ltd, Key Employee Biographies
Imugene Ltd, Major Products and Services
Imugene Ltd, History
Imugene Ltd, Subsidiaries
Imugene Ltd, Key Competitors
Imugene Ltd, Ratios based on current share price
Imugene Ltd, Annual Ratios
Imugene Ltd, Annual Ratios (Cont...1)
Imugene Ltd, Interim Ratios
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Imugene Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Imugene Ltd, Performance Chart (2013 - 2017)
Imugene Ltd, Ratio Charts
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report